Beijing WBL Peking University Biotech Co. Ltd.(WPU), is a high-tech joint venture of the renowned Peking University of China, the WBL Corporation Limited of Singapore and the Beijing Enterprises Holdings Limited of Hong Kong which was founded in 1994 with registered capital of RMB 80 million.
As a modern Chinese medicine enterprise, WPU is devoted herself to the exploration and investigation of the traditional Chinese medical resources and has made a series of breakthrough in terms of both theory and methodology by combining the merits of traditional Chinese and western medicine.
Xuezhikang capsule, the regulating-lipid medicine with international advanced levels, is a leading product of WPU. It is regarded as an excellent high-tech achievement of Peking University developed by Professor Zhang Maoliang of Peking University and other people by combining modern biotech and Chinese traditional medicine. WPU has steadily built a reputation for scientific inquiry and integrity. Many years of testing and development by leading researchers at WPU and major China have LED to breakthroughs in every aspect of natural product development.
The pharmaceutical factory of WPU is a modern factory which was built and managed strictly in accordance with GMP standards. It has ultra-clean workshops and is equipped with advanced facilities. The quality control of the production process is conducted through the use of advanced HPLC which guarantees the best quality of the medicine produced. The natural raw materials used in the production which are with no element of chemical synthesis. Furthermore the manufacturing process utilizes modern technology, which ensures no wastage or other industrial pollution and as such it is environmental friendly.
WPU manufactures a cholesterol-reducing medical preparation through a patented natural fermentation process classified as a "National Trade Secret" by the Chinese Government. It is marketed in China as "Xuezhikang". This award-winning product continued to generate much acclaim from the domestic and international medical community since its launch in the year of 1996. Xuezhikang is now included in the "Basic Drug" list which will make the purchase of Xuezhikang reimbursable under China's national healthcare programme. Apart from its domestic market, export sales to the US, Taiwan, Korea and Hong Kong and other parts of Asia as "dietary supplement" increased year by year.
In Oct.1996, Xuezhikang was also selected as the Only blood lipid regulating medicine strongly promoted by the Chinese Medical Association under its Key National Promotional Programme. In addition, Xuezhikang has been chosen as an official clinical medicine used for preventive treatment of stage-two coronary heart disease under the National Ninth five-year Project where q 5-year research involving clinical observations of 6,000 patients is now being performed in more than 60 famous hospitals across the nation.
With the efforts to manufacture modern Chinese medicine with the standard of safety, effectiveness, quality-controlable and stability, WPU is ready for sincere cooperation and bilateral development with friends of various sectors in order to contribute to the Chinese medical community as well as the wellbeing of the society and health of mankind.
As a modern Chinese medicine enterprise, WPU is devoted herself to the exploration and investigation of the traditional Chinese medical resources and has made a series of breakthrough in terms of both theory and methodology by combining the merits of traditional Chinese and western medicine.
Xuezhikang capsule, the regulating-lipid medicine with international advanced levels, is a leading product of WPU. It is regarded as an excellent high-tech achievement of Peking University developed by Professor Zhang Maoliang of Peking University and other people by combining modern biotech and Chinese traditional medicine. WPU has steadily built a reputation for scientific inquiry and integrity. Many years of testing and development by leading researchers at WPU and major China have LED to breakthroughs in every aspect of natural product development.
The pharmaceutical factory of WPU is a modern factory which was built and managed strictly in accordance with GMP standards. It has ultra-clean workshops and is equipped with advanced facilities. The quality control of the production process is conducted through the use of advanced HPLC which guarantees the best quality of the medicine produced. The natural raw materials used in the production which are with no element of chemical synthesis. Furthermore the manufacturing process utilizes modern technology, which ensures no wastage or other industrial pollution and as such it is environmental friendly.
WPU manufactures a cholesterol-reducing medical preparation through a patented natural fermentation process classified as a "National Trade Secret" by the Chinese Government. It is marketed in China as "Xuezhikang". This award-winning product continued to generate much acclaim from the domestic and international medical community since its launch in the year of 1996. Xuezhikang is now included in the "Basic Drug" list which will make the purchase of Xuezhikang reimbursable under China's national healthcare programme. Apart from its domestic market, export sales to the US, Taiwan, Korea and Hong Kong and other parts of Asia as "dietary supplement" increased year by year.
In Oct.1996, Xuezhikang was also selected as the Only blood lipid regulating medicine strongly promoted by the Chinese Medical Association under its Key National Promotional Programme. In addition, Xuezhikang has been chosen as an official clinical medicine used for preventive treatment of stage-two coronary heart disease under the National Ninth five-year Project where q 5-year research involving clinical observations of 6,000 patients is now being performed in more than 60 famous hospitals across the nation.
With the efforts to manufacture modern Chinese medicine with the standard of safety, effectiveness, quality-controlable and stability, WPU is ready for sincere cooperation and bilateral development with friends of various sectors in order to contribute to the Chinese medical community as well as the wellbeing of the society and health of mankind.
| Company Name | WBL Peking University Biotech Co.,Ltd. (WPU) |
|---|---|
| Business Type | Manufacturer |
| Main Products | Medicine |
| Total No. Employees | 101 - 500 People |
| City | Beijing |
| Province/State | Beijing |
| Country/Region | China (Mainland) |
| Company Website | http://www.wpu.com.cn |
| Contact Person | Mr. DONG WANG |
| Telephone | 8************6 View all, please login |
| Fax | 86-10-68748272 |
| Street Address | Fl.10 Aero Space Great Wall Bldg. No.30 South Haidian Rd. |
| Zip Code | 100080 |
| sell123 URL | http://www.sell123.org/company/China-Mainland/135236.htm |
Suppliers By Region
- In Beijing
- Beijing ...(52)
- Tongzhou(43)
- Beiing(41)
- bei jing(31)
- In China (Mainland)
- Guangdong(89843)
- Zhejiang(69994)
- Jiangsu(25823)
- Shandong(21737)
- Fujian(14410)
- Shanghai(13222)
- Hebei(9028)
- Henan(5897)
- Beijing(4456)
- Tianjin(3327)
- Anhui(3295)
- Liaoning(2913)
- Hubei(2496)
- Shaanxi(2179)
- Hunan(2019)
- Sichuan(1938)
- Chongqing(1677)
- Jiangxi(1657)
- Guangxi(1331)
- Shanxi(656)
- Yunnan(369)
- Jilin(302)
- Heilongj...(281)
- Inner Mo...(194)
- Gansu(127)
- Guizhou(118)
- Hainan(101)
- Xinjiang(94)
- Ningxia(89)
By Business Type
- In Beijing
- Manufacturer(2861)
- Trading Company(3060)
- Wholesaler(362)
- Agent(222)
- Buyer(68)
- In China (Mainland)
- Manufacturer(232295)
- Trading Company(167254)
- Wholesaler(16101)
- Agent(7658)
- Buyer(4057)
Related Suppliers By Main Products
| Medicine (320) | China (Mainland) (39) | Shanghai Trifecta I& E Co., Ltd.Zhuhai Aofute Medtech Co., Ltd.Shanghai Trifecta I&E Co., Ltd. |
|---|